Survival In Asbestos-Related Cancer Improved By Chemo Combination (2/18/07)

A Phase I and Pharmocokinetic study of Pemetrexed (Alimta) Plus Irinotecan (Camptosar) in Patients with Advanced Solid Malignancies  (2/15/07)

Raltitrexed and Pemetrexed Studies in Mesothelioma Have Not Shown Improved Quality of Life nor Prolonged Survival Compared With Effective Pleurodesis With Thoracoscopic Talc Poudrage (10/5/06)

England Limits Usage of Alimta for Mesothelioma, Eli Lilly Appeals (6/26/06)

Alimta® and Paraplatin® Effective and Well-Tolerated in Mesothelioma (3/22/06)

Pemetrexed in Malignant Pleural Mesothelioma (1/31/05)

Alimta(R) Showed Advances over Taxotere(R) in Second-Line Non-Small Cell Lung Cancer Study (5/3/04)

Puget Sound Cancer Centers Plays Significant Role in Clinical Testing Of Newly Approved Cancer Drug; FDA Approves Alimta for Treatment of Asbestos-Related Cancer (3/19/04)

FDA OKs Lilly Drug for Asbestos-Related Cancer (2/5/04)

Lilly Initiative Provides Investigational Agent Free of Charge for Medically Eligible Patients with Mesothelioma (10/15/03)

Drug Combination Extends Survival in Mesothelioma (7/16/03)

MARF Doctor Hails Alimta as "A New Standard Therapy" for Treating Mesothelioma; Lilly Makes Drug Available through Expanded Access Program. Indianapolis, Indiana, November 14, 2002 (11/20/02)

Thoracic Expert: Patients With Asbestos-Related Cancer Report Better Quality of Life With Alimta+Cisplatin (6/13/03)

Lilly Offers Alimta On Expanded Access Basis (7/10/02)